| Synonyms |
U2OS/ATRkd; U2OS ATRkd |
| Accession |
CVCL_A5LZ |
| Resource Identification Initiative |
To cite this cell line use: U2OS-ATRkd (RRID:CVCL_A5LZ) |
| Comments |
Population: Caucasian.Genetic integration: Method=Transfection; Gene=HGNC; 882; ATR (Note=With p.Asp2494Glu = ATRkd).Genetic integration: Method=Transfection; Gene=UniProtKB; P00552; Transposon Tn5 neo.Derived from site: In situ; Bone, tibia; UBERON=UBERON_0000979. |
| Sequence variations |
Mutation; HGNC; 9277; PPM1D; Simple; p.Arg458Ter (c.1372C>T); ClinVar=VCV002445214; Zygosity=Heterozygous (from parent cell line). |
| Disease |
Osteosarcoma (NCIt: C9145)Osteosarcoma (ORDO: Orphanet_668) |
| Species of origin |
Homo sapiens (Human) (NCBI Taxonomy: 9606) |
| Hierarchy |
Parent: CVCL_0042 (U2OS) |
| Sex of cell |
Female |
| Age at sampling |
15Y |
| Category |
Cancer cell line |
| Publications |
PubMed=11481475; DOI=10.1073/pnas.161281798; PMCID=PMC55378 Nghiem P., Park P.K., Kim Y.-S., Vaziri C., Schreiber S.L. ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. Proc. Natl. Acad. Sci. U.S.A. 98:9092-9097(2001) |
| Cross-references |
|
| Anatomy/cell type resources |
BTO; BTO:0003696 |
| Encyclopedic resources |
Wikidata; Q107117180 |
| Entry history |
|
| Entry creation |
20-May-2021 |
| Last entry update |
10-Sep-2024 |
| Version number |
6 |